Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 8.74
NDZ's Cash to Debt is ranked higher than
72% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. NDZ: 8.74 )
NDZ' s 10-Year Cash to Debt Range
Min: 0.1   Max: 8.74
Current: 8.74

0.1
8.74
Equity to Asset 0.77
NDZ's Equity to Asset is ranked higher than
80% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. NDZ: 0.77 )
NDZ' s 10-Year Equity to Asset Range
Min: 0.43   Max: 0.77
Current: 0.77

0.43
0.77
Interest Coverage 52.15
NDZ's Interest Coverage is ranked higher than
62% of the 103 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 116.56 vs. NDZ: 52.15 )
NDZ' s 10-Year Interest Coverage Range
Min: 0.25   Max: 52.15
Current: 52.15

0.25
52.15
F-Score: 6
Z-Score: 5.92
M-Score: -0.42
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 101.12
NDZ's Operating margin (%) is ranked higher than
99% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.89 vs. NDZ: 101.12 )
NDZ' s 10-Year Operating margin (%) Range
Min: -52.7   Max: 94.8
Current: 101.12

-52.7
94.8
Net-margin (%) 101.72
NDZ's Net-margin (%) is ranked higher than
99% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.31 vs. NDZ: 101.72 )
NDZ' s 10-Year Net-margin (%) Range
Min: -96.53   Max: 101.87
Current: 101.72

-96.53
101.87
ROE (%) 69.22
NDZ's ROE (%) is ranked higher than
99% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.65 vs. NDZ: 69.22 )
NDZ' s 10-Year ROE (%) Range
Min: -42.57   Max: 73.58
Current: 69.22

-42.57
73.58
ROA (%) 48.94
NDZ's ROA (%) is ranked higher than
99% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.89 vs. NDZ: 48.94 )
NDZ' s 10-Year ROA (%) Range
Min: -25.89   Max: 46.31
Current: 48.94

-25.89
46.31
ROC (Joel Greenblatt) (%) 336.98
NDZ's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 188 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.61 vs. NDZ: 336.98 )
NDZ' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -144.6   Max: 311.26
Current: 336.98

-144.6
311.26
Revenue Growth (%) 13.00
NDZ's Revenue Growth (%) is ranked higher than
87% of the 152 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.60 vs. NDZ: 13.00 )
NDZ' s 10-Year Revenue Growth (%) Range
Min: -34.8   Max: 24.5
Current: 13

-34.8
24.5
» NDZ's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

NDZ Guru Trades in Q3 2013

Steven Cohen 14,549 sh (New)
Jim Simons 355,700 sh (-24.59%)
Chuck Royce 7,530 sh (-83.68%)
» More
Q4 2013

NDZ Guru Trades in Q4 2013

Steven Cohen 15,640 sh (+7.5%)
Chuck Royce 7,530 sh (unchged)
Jim Simons 269,802 sh (-24.15%)
» More
Q1 2014

NDZ Guru Trades in Q1 2014

Jim Simons 451,500 sh (+67.34%)
Chuck Royce Sold Out
Steven Cohen Sold Out
» More
Q2 2014

NDZ Guru Trades in Q2 2014

Jean-Marie Eveillard 200,000 sh (New)
Mario Gabelli 302,900 sh (New)
Jim Simons 356,746 sh (-20.99%)
» More
» Details

Insider Trades

Latest Guru Trades with NDZ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Mario Gabelli 2014-06-30 New Buy0.02%$11.27 - $12.77 $ 12.997%302900
Jean-Marie Eveillard 2014-06-30 New Buy0.01%$11.27 - $12.77 $ 12.997%200000
George Soros 2011-12-31 Sold Out 0.01%$8.01 - $9.26 $ 12.9948%0
George Soros 2011-09-30 Add 125.13%$8.41 - $11.1 $ 12.9936%43000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 3.00
NDZ's P/E(ttm) is ranked higher than
99% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NDZ: 3.00 )
NDZ' s 10-Year P/E(ttm) Range
Min: 1.95   Max: 8089.43
Current: 3

1.95
8089.43
P/B 1.70
NDZ's P/B is ranked higher than
89% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.00 vs. NDZ: 1.70 )
NDZ' s 10-Year P/B Range
Min: 0.51   Max: 2.45
Current: 1.7

0.51
2.45
P/S 3.10
NDZ's P/S is ranked higher than
71% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.96 vs. NDZ: 3.10 )
NDZ' s 10-Year P/S Range
Min: 0.46   Max: 7.64
Current: 3.1

0.46
7.64
PFCF 13.42
NDZ's PFCF is ranked higher than
96% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NDZ: 13.42 )
NDZ' s 10-Year PFCF Range
Min: 3.67   Max: 759
Current: 13.42

3.67
759
EV-to-EBIT 1.95
NDZ's EV-to-EBIT is ranked higher than
99% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NDZ: 1.95 )
NDZ' s 10-Year EV-to-EBIT Range
Min: -134   Max: 329.9
Current: 1.95

-134
329.9
Current Ratio 4.39
NDZ's Current Ratio is ranked higher than
83% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.56 vs. NDZ: 4.39 )
NDZ' s 10-Year Current Ratio Range
Min: 0.86   Max: 6.13
Current: 4.39

0.86
6.13
Quick Ratio 4.02
NDZ's Quick Ratio is ranked higher than
83% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.29 vs. NDZ: 4.02 )
NDZ' s 10-Year Quick Ratio Range
Min: 0.66   Max: 5.5
Current: 4.02

0.66
5.5

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.80
NDZ's Dividend Yield is ranked higher than
56% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.28 vs. NDZ: 0.80 )
NDZ' s 10-Year Dividend Yield Range
Min: 0.42   Max: 6.09
Current: 0.8

0.42
6.09
Yield on cost (5-Year) 0.80
NDZ's Yield on cost (5-Year) is ranked lower than
55% of the 62 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. NDZ: 0.80 )
NDZ' s 10-Year Yield on cost (5-Year) Range
Min: 0.37   Max: 5.93
Current: 0.8

0.37
5.93
Share Buyback Rate 11.50
NDZ's Share Buyback Rate is ranked higher than
99% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.70 vs. NDZ: 11.50 )
NDZ' s 10-Year Share Buyback Rate Range
Min: 19.8   Max: -11.7
Current: 11.5

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.37
NDZ's Price/Net Cash is ranked higher than
95% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NDZ: 4.37 )
NDZ' s 10-Year Price/Net Cash Range
Min: 3.07   Max: 4.01
Current: 4.37

3.07
4.01
Price/Net Current Asset Value 3.45
NDZ's Price/Net Current Asset Value is ranked higher than
95% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NDZ: 3.45 )
NDZ' s 10-Year Price/Net Current Asset Value Range
Min: 2.42   Max: 3.04
Current: 3.45

2.42
3.04
Price/Tangible Book 1.71
NDZ's Price/Tangible Book is ranked higher than
92% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.92 vs. NDZ: 1.71 )
NDZ' s 10-Year Price/Tangible Book Range
Min: 0.98   Max: 13.43
Current: 1.71

0.98
13.43
Price/DCF (Projected) 1.17
NDZ's Price/DCF (Projected) is ranked higher than
93% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NDZ: 1.17 )
NDZ' s 10-Year Price/DCF (Projected) Range
Min: 0.51   Max: 5.18
Current: 1.17

0.51
5.18
Price/Median PS Value 1.50
NDZ's Price/Median PS Value is ranked higher than
64% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.26 vs. NDZ: 1.50 )
NDZ' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 2.73
Current: 1.5

0.22
2.73
Price/Graham Number 0.48
NDZ's Price/Graham Number is ranked higher than
98% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. NDZ: 0.48 )
NDZ' s 10-Year Price/Graham Number Range
Min: 0.33   Max: 7.12
Current: 0.48

0.33
7.12
Earnings Yield (Greenblatt) 51.30
NDZ's Earnings Yield (Greenblatt) is ranked higher than
99% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.70 vs. NDZ: 51.30 )
NDZ' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 112.9
Current: 51.3

0.3
112.9
Forward Rate of Return (Yacktman) 1.68
NDZ's Forward Rate of Return (Yacktman) is ranked higher than
72% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.68 vs. NDZ: 1.68 )
NDZ' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -31.6   Max: 7.3
Current: 1.68

-31.6
7.3

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:NDN.Canada, XMD.Germany
Nordion, Inc., formerly known as MDS Inc., was incorporated on April 17, 1969 under the laws of the Province of Ontario under the name Medical Data Sciences Limited. The Company changed its name to MDS Health Group Limited in April of 1973 and to MDS Inc. in November 1996. The Company is a global health science company that provides products used for the prevention, diagnosis and treatment of disease. It is a provider of targeted therapies, sterilization technologies and medical isotopes that benefit the lives of millions of people in more than 60 countries around the world.
» More Articles for NYSE:NDZ

Headlines

Articles On GuruFocus.com
The Best Dividends on March 19, 2012 Mar 16 2012 
8 Healthcare Dividend Stocks Close To 52-Week Low Sep 03 2011 

More From Other Websites
Sterigenics International Completes $826 Million Acquisition of Nordion Inc. Aug 06 2014
Nordion Announces Completion of Acquisition by Sterigenics International Aug 06 2014
Nordion Receives Investment Canada Act Approval and Announces Expected Closing Date for Acquisition... Aug 01 2014
STHI Holding Corporation -- Moody's assigns B2 to STHI's new bank debt; confirms B2 CFR; outlook... Jul 17 2014
Lorillard and Fastenal are big market movers Jul 11 2014
Lorillard and Fastenal are big market movers Jul 11 2014
Midday movers: Amazon.com, Ford Motor, URS & More Jul 11 2014
Nordion Announces Termination of Hart-Scott-Rodino Act Waiting Period and Receipt of No-Action... Jul 11 2014
Nordion Receives Second Request Under Hart-Scott-Rodino Act Jun 27 2014
Nordion receives second request under Hart-Scott-Rodino Act Jun 27 2014
Nordion Receives Second Request Under Hart-Scott-Rodino Act Jun 27 2014
Why AQR Capital liquidates position in Marvell Technology Jun 18 2014
Must-know: Why AQR Capital exits position in LyondellBasell Jun 18 2014
Why AQR Capital initiates new position in Nordion Jun 18 2014
Why AQR Capital starts new position in Riverbed Technology Jun 17 2014
Overview: AQR Capital Management positions in 1Q14 Jun 17 2014
Nordion receives final court approval for acquisition by Sterigenics Jun 11 2014
Nordion Receives Final Court Approval for Acquisition by Sterigenics Jun 11 2014
Nordion Provides Detailed Results from Annual and Special Meeting of Shareholders Jun 06 2014
Nordion shareholders back $805 mln takeover by Sterigenics Jun 06 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK